Trade Corvus Pharmaceuticals, Inc. - CRVS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0332 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.3884 |
| Open | 4.2984 |
| 1-Year Change | 88.97% |
| Day's Range | 4.1584 - 4.3184 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 4.1684 | -0.1400 | -3.25% | 4.3084 | 4.3684 | 4.1484 |
| Feb 20, 2025 | 4.3884 | -0.0500 | -1.13% | 4.4384 | 4.4984 | 4.3284 |
| Feb 19, 2025 | 4.4984 | -0.1900 | -4.05% | 4.6884 | 4.7184 | 4.4984 |
| Feb 18, 2025 | 4.7584 | -0.0400 | -0.83% | 4.7984 | 4.9484 | 4.7384 |
| Feb 14, 2025 | 4.8584 | -0.0500 | -1.02% | 4.9084 | 4.9884 | 4.5784 |
| Feb 13, 2025 | 4.8984 | -0.1300 | -2.59% | 5.0284 | 5.0384 | 4.8784 |
| Feb 12, 2025 | 5.0184 | 0.1200 | 2.45% | 4.8984 | 5.1384 | 4.8884 |
| Feb 11, 2025 | 4.9384 | -0.0500 | -1.00% | 4.9884 | 5.2084 | 4.9084 |
| Feb 10, 2025 | 5.0184 | -0.1500 | -2.90% | 5.1684 | 5.2284 | 4.9884 |
| Feb 7, 2025 | 5.1784 | -0.1300 | -2.45% | 5.3084 | 5.4284 | 5.1684 |
| Feb 6, 2025 | 5.3684 | -0.0800 | -1.47% | 5.4484 | 5.5984 | 5.3384 |
| Feb 5, 2025 | 5.4484 | 0.0600 | 1.11% | 5.3884 | 5.6084 | 5.3884 |
| Feb 4, 2025 | 5.3084 | 0.2700 | 5.36% | 5.0384 | 5.3884 | 5.0384 |
| Feb 3, 2025 | 5.0684 | 0.0600 | 1.20% | 5.0084 | 5.2684 | 4.9884 |
| Jan 31, 2025 | 5.3484 | 0.0900 | 1.71% | 5.2584 | 5.5384 | 5.2384 |
| Jan 30, 2025 | 5.2784 | 0.2400 | 4.76% | 5.0384 | 5.4084 | 5.0384 |
| Jan 29, 2025 | 5.0484 | -0.1000 | -1.94% | 5.1484 | 5.1484 | 4.9484 |
| Jan 28, 2025 | 5.0284 | -0.0200 | -0.40% | 5.0484 | 5.0984 | 4.9384 |
| Jan 27, 2025 | 5.0484 | -0.0900 | -1.75% | 5.1384 | 5.4384 | 4.9884 |
| Jan 24, 2025 | 5.2684 | 0.0700 | 1.35% | 5.1984 | 5.4384 | 5.1984 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Corvus Pharmaceuticals, Inc. Company profile
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.
| Industry: | Biotechnology & Medical Research (NEC) |
863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com